nasal-spray version of the Covid-19 vaccine developed by Oxford University researchers and AstraZeneca Plc, on human beings did not yield the desired protection, according to the news agency Reuters.
The University of Oxford, in an official statement, said that the antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in the first of usually three phases of clinical testing.
Also, it also showed that the immune response measured in the blood was weaker than that from a shot-in-the-arm vaccination, the statement said as quoted by Reuters.
However, researchers across the world had high hopes for the nasal spray Covid-19 vaccine because the method is believed to potentially prevent infection and not just disease as it may prompt an immune response directly in the airways, where the virus enters the body.